| Remdesivir for the treatment of Covid-19 JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1826, 2020 | 5945 | 2020 |
| Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021 | 1762 | 2021 |
| Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial AC Kalil, AK Mehta, TF Patterson, N Erdmann, CA Gomez, MK Jain, ... The lancet respiratory medicine 9 (12), 1365-1376, 2021 | 141 | 2021 |
| Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial CR Wolfe, KM Tomashek, TF Patterson, CA Gomez, VC Marconi, MK Jain, ... The lancet respiratory medicine 10 (9), 888-899, 2022 | 87 | 2022 |
| SARS-CoV-2 BA. 1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... Science Translational Medicine 14 (645), eabn8543, 2022 | 78 | 2022 |
| SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... BioRxiv, 2021 | 41 | 2021 |
| Preemptive tecovirimat use in an active duty service member who presented with acute myeloid leukemia after smallpox vaccination DA Lindholm, RD Fisher, JR Montgomery, W Davidson, PA Yu, YC Yu, ... Clinical Infectious Diseases 69 (12), 2205-2207, 2019 | 38 | 2019 |
| Durability of SARS-CoV-2–specific T-cell responses at 12 months postinfection Z Lu, ED Laing, J Pena DaMata, K Pohida, MS Tso, EC Samuels, NJ Epsi, ... The Journal of Infectious Diseases 224 (12), 2010-2019, 2021 | 37 | 2021 |
| Persistent COVID-19 symptoms at 6 months after onset and the role of vaccination before or after SARS-CoV-2 infection SA Richard, SD Pollett, AC Fries, CM Berjohn, RC Maves, T Lalani, ... JAMA network open 6 (1), e2251360-e2251360, 2023 | 36 | 2023 |
| Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history W Wang, S Lusvarghi, R Subramanian, NJ Epsi, R Wang, E Goguet, ... Cell host & microbe 30 (12), 1745-1758. e7, 2022 | 32 | 2022 |
| DoD COVID-19 practice management guide, clinical management of COVID-19 RI Matos, KK Chung, J Benjamin Def Heal Agency, 2020 | 27 | 2020 |
| SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity ED Laing, NJ Epsi, SA Richard, EC Samuels, W Wang, R Vassell, ... medrxiv, 2021.04. 27.21256207, 2021 | 24 | 2021 |
| Mosquito exposure and chikungunya and dengue infection among travelers during the chikungunya outbreak in the Americas DA Lindholm, T Myers, S Widjaja, EM Grant, K Telu, T Lalani, J Fraser, ... The American journal of tropical medicine and hygiene 96 (4), 903, 2017 | 23 | 2017 |
| Understanding'hybrid immunity': comparison and predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19 vaccines. NJ Epsi, SA Richard, DA Lindholm, K Mende, A Ganesan, N Huprikar, ... Clin. infect. dis, 2022 | 22 | 2022 |
| COVID-19 outcomes among US Military Health System beneficiaries include complications across multiple organ systems and substantial functional impairment SA Richard, SD Pollett, CA Lanteri, EV Millar, AC Fries, RC Maves, ... Open Forum Infectious Diseases 8 (12), ofab556, 2021 | 21 | 2021 |
| Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) instrument in patients with coronavirus disease 2019 SA Richard, NJ Epsi, S Pollett, DA Lindholm, AMW Malloy, R Maves, ... Open Forum Infectious Diseases 8 (12), ofab517, 2021 | 17 | 2021 |
| Performance analysis of the national early warning score and modified early warning score in the adaptive COVID-19 treatment trial cohort CJ Colombo, RE Colombo, RC Maves, AR Branche, SH Cohen, MC Elie, ... Critical Care Explorations 3 (7), e0474, 2021 | 16 | 2021 |
| Understanding “hybrid immunity”: comparison and predictors of humoral immune responses to severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) and coronavirus … NJ Epsi, SA Richard, DA Lindholm, K Mende, A Ganesan, N Huprikar, ... Clinical Infectious Diseases 76 (3), e439-e449, 2023 | 13 | 2023 |
| Clinical, immunological, and virological SARS-CoV-2 phenotypes in obese and nonobese military health system beneficiaries NJ Epsi, SA Richard, ED Laing, AC Fries, E Millar, MP Simons, C English, ... The Journal of infectious diseases 224 (9), 1462-1472, 2021 | 13 | 2021 |
| Case report: a case of recurrent Strongyloides stercoralis colitis in a patient with multiple myeloma K Glenn, DA Lindholm, G Meis, L Watts, N Conger The American Journal of Tropical Medicine and Hygiene 97 (5), 1619, 2017 | 12 | 2017 |
